Abbvie pulls plug on Swedish R&D partnership

Swedish biotech firm Bioarctic expresses its disappointment over Abbvie’s decision to terminate a collaborative partnership on potential Parkinson’s treatments.

Photo: Abbvie / PR

US-based Abbvie has decided to end a collaboration with Swedish biotech firm Bioartic on the latter’s portfolio of alpha-synuclein antibodies, the company has announced in a press release.

The portfolio targeted Parkinson’s diseases and other indications, and included monoclonal antibody candidate ABBV-0805, the collaboration’s lead asset.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs